drugset / Trial / NCT01180790
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
Phase 2
Completed
122 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Evaluate safety, tolerability, and antiviral response of ACH-0141625 compared to standard of care in hepatitis C virus (HCV)-positive participants.
Timeline
- Start
- 2010-09
- Primary completion
- 2012-03
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sovaprevir | Small molecule | 200 mg | Oral |
| Subject | Sovaprevir | Small molecule | 400 mg | Oral |
| Subject | Sovaprevir | Small molecule | 800 mg | Oral |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Background | Ribavirin | Small molecule | 400 mg | Oral |
| Background | Ribavirin | Small molecule | 600 mg | Oral |